Shots:
- Cytiva and Yoshindo sign a FlexFactory contract to support the establishment of domestic biosimilar drug substance manufacturing in Japan. The investment is partly supported by Japan’s MHLW
- Yoshindo plans to supply biosimilars from its Toyama plant starting in 2028, supporting a stable and affordable biologics supply in Japan
- Cytiva’s FlexFactory platform uses modular bioprocessing technologies to support faster transition from facility design to GMP production. Following a design phase completed in early 2026, Yoshindo was able to outline its manufacturing operations and estimate key requirements
Ref: Cytiva| Image: Cytiva and Yoshindo | Press Release
Related News:- Bio-Thera Expands Collaboration with Intas Pharmaceuticals for the Commercialization of BAT2506 (Biosimilar, Simponi) in India
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
